SKYRIZI (risankizumab) is a selective IL-23/p19 inhibitor indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Dr. Gooderham
Dr. Melinda Gooderham, an expert dermatologist with personal clinical experience using SKYRIZI, shares her perspective
I want to receive more information via a product specialist